HLA-DRB1*03 is associated with systemic lupus erythematosus and anti -SSB production in South Tunisia

Authors

  • Hend Hachicha Immunology Departement CHU Habib Bourguiba, Sfax, UR12SP14, Habib Bourguiba university Hospital of Sfax, Sfax, Tunisia
  • Arwa Kammoun Histocompatibility department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Nadia Mahfoudh Histocompatibility department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Sameh Marzouk Internal Medecine department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Hajer Fourati UR12SP14, Habib Bourguiba university Hospital of Sfax, Sfax, Tunisia
  • Samy Haddouk Immunology department, Habib Bourguiba university Hospital of Sfax, Sfax,Tunisia UR12SP14, Habib Bourguiba university Hospital of Sfax, Sfax, Tunisia
  • Raouia Fakhfakh UR12SP14, Habib Bourguiba university Hospital of Sfax, Sfax, Tunisia
  • Sawsan Feki Immunology department, Habib Bourguiba university Hospital of Sfax, Sfax,Tunisia
  • Faten Frikha Internal Medecine department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Lilia Gaddour Histocompatibility department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Feiza Hakim Histocompatibility department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Zouheir Bahloul Internal Medecine department, Hedi Chaker university Hospital, University of Sfax, Tunisia
  • Hafedh Makni
  • Hatem Masmoudi

Keywords:

Association, HLA, systemic lupus erythematosus, disease clinical expression

Abstract

Systemic Lupus erythematosus (SLE) is an autoimmune disease with various presentations. This variation is due to the interaction of hormonal, environmental and genetic factors. Associations between human leucocyte antigens and SLE have long been recognized in different ethnic populations and have been suggested to represent the most important association.

Objectives: The objectives of this paper were to determine susceptibility and protection HLA class II markers for SLE and to highlight, for the first time, associations between HLA alleles and clinical and serological features in South Tunisia.

Methods:  We conducted a case-control study on 75 SLE patients and 123 healthy controls. The HLA class II DRB1/DQB1 of all patients and controls was genotyped using PCR-SSP technique. Statistical analysis was performed using SPSS software.

Results: HLA-DRB1*03 was the principal classII allele associated with the genetic susceptibility to SLE (pc=0.02; OR=2.57; CI=(1.39-4.75); this allele was also associated with anti-SSB production (p=0.016; OR=4.00; CI=(1.24-12.96)). HLA- DRB1*01 was significantly more expressed in SLE patients with neurologic disorders (p=0.013; OR=20.25; CI= (1.87-219.21)). No allele was found to be protective against SLE in our study group.

Conclusion:  Our results show that in south Tunisia SLE is associated with HLA-DRB1*03 and that some clinical features of SLE may be influenced by specific DRB1 and DQB1 alleles.

Downloads

Published

2018-01-15

How to Cite

Hachicha, H., Kammoun, A., Mahfoudh, N., Marzouk, S., Fourati, H., Haddouk, S., Fakhfakh, R., Feki, S., Frikha, F., Gaddour, L., Hakim, F., Bahloul, Z., Makni, H., & Masmoudi, H. (2018). HLA-DRB1*03 is associated with systemic lupus erythematosus and anti -SSB production in South Tunisia. International Journal of Health Sciences, 12(1). Retrieved from https://pub.qu.edu.sa/index.php/journal/article/view/1982

Issue

Vol. 12 No. 1 (2018): Jan-Feb

Section

Original Paper

License


Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).